{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:39:34Z","timestamp":1787683174038,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.humpath.2020.12.006","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T17:40:14Z","timestamp":1608658814000},"page":"84-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["TSC\/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+\/CK20-\/vimentin-: a validation study"],"prefix":"10.1016","volume":"115","author":[{"given":"Melissa Y.","family":"Tjota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-8431","authenticated-orcid":false,"given":"Pankhuri","family":"Wanjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-9413","authenticated-orcid":false,"given":"Tatjana","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.12.006_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2020.12.006_bib2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.humpath.2020.12.006_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/his.13362","article-title":"Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases","volume":"72","author":"Perrino","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.12.006_bib4","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.5858\/arpa.2019-0203-RA","article-title":"Eosinophilic kidney tumors: old and new","volume":"143","author":"Iczkowski","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2020.12.006_bib5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5858\/arpa.2013-0653-RA","article-title":"Diagnostic approach to eosinophilic renal neoplasms","volume":"138","author":"Kryvenko","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2020.12.006_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","article-title":"Tuberous sclerosis\u2013associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients","volume":"38","author":"Guo","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/PAS.0000000000000508","article-title":"Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0000000000000838","article-title":"Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity","volume":"41","author":"Trpkov","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PAS.0000000000001170","article-title":"Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm","volume":"43","author":"Chen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib10","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/PAS.0000000000001111","article-title":"Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum","volume":"42","author":"Palsgrove","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/PAS.0000000000001067","article-title":"Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations?","volume":"42","author":"Parilla","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2018.06.007","article-title":"Somatic Bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2020.12.006_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001457","article-title":"Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study","author":"Tjota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","article-title":"Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays","volume":"19","author":"Kadri","year":"2017","journal-title":"J Mol Diagn JMD"},{"key":"10.1016\/j.humpath.2020.12.006_bib15","first-page":"935","article-title":"Review of renal oncocytoma with focus on clinical and pathobiological aspects","volume":"18","author":"Kuroda","year":"2003","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.2017.96","article-title":"Modern pathologic diagnosis of renal oncocytoma","volume":"4","author":"Wobker","year":"2017","journal-title":"J. Kidney Cancer VHL"},{"key":"10.1016\/j.humpath.2020.12.006_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-2042.2010.02574.x","article-title":"Molecular pathology of renal oncocytoma: a review","volume":"17","author":"Yusenko","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.humpath.2020.12.006_bib18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1442-2042.2012.03079.x","article-title":"Chromophobe renal cell carcinoma: a review of an uncommon entity","volume":"19","author":"Vera-Badillo","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.humpath.2020.12.006_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/jclinpath-2015-203585","article-title":"A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma","volume":"69","author":"Ng","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Canc Cell"},{"key":"10.1016\/j.humpath.2020.12.006_bib21","first-page":"592","article-title":"Molecular pathology of chromophobe renal cell carcinoma: a review","volume":"17","author":"Yusenko","year":"2010","journal-title":"Int J Urol Off J Jpn Urol Assoc."},{"key":"10.1016\/j.humpath.2020.12.006_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92688","article-title":"Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma","volume":"2","author":"Casuscelli","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.humpath.2020.12.006_bib23","first-page":"8311","article-title":"Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.12.006_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010168","article-title":"ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO classification","volume":"12","author":"Siadat","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2020.12.006_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/his.13876","article-title":"High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex","volume":"75","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.12.006_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00428-018-2456-4","article-title":"\u201cHigh-grade oncocytic renal tumor\u201d: morphologic, immunohistochemical, and molecular genetic study of 14 cases","volume":"473","author":"He","year":"2018","journal-title":"Virchows Arch Int J Pathol."},{"key":"10.1016\/j.humpath.2020.12.006_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.13865","article-title":"Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?","volume":"75","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.12.006_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101492","article-title":"Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype","volume":"11","author":"Ohashi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2020.12.006_bib30","first-page":"1","article-title":"Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome","author":"Roldan-Romero","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.12.006_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2020.12.006_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/thy.11.32","article-title":"mTOR inhibitors in renal cell carcinoma","volume":"8","author":"Battelli","year":"2011","journal-title":"Therapy"},{"key":"10.1016\/j.humpath.2020.12.006_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.12.006_bib34","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma","volume":"22","author":"Kwiatkowski","year":"2016","journal-title":"Clin. Cancer Res Off J Am Assoc Cancer Res."},{"key":"10.1016\/j.humpath.2020.12.006_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.6004\/jnccn.2017.7041","article-title":"Biallelic TSC2 mutations in a patient with chromophobe renal cell carcinoma showing extraordinary response to temsirolimus","volume":"16","author":"Maroto","year":"2018","journal-title":"J Natl Compr Cancer Netw JNCCN"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720302598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720302598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:39:19Z","timestamp":1758645559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720302598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"alternative-id":["S0046817720302598"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.12.006","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TSC\/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+\/CK20-\/vimentin-: a validation study","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}